<DOC>
	<DOCNO>NCT00303849</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose melphalan give together carboplatin , etoposide phosphate , mannitol , sodium thiosulfate see well work treat patient previously treat brain tumor . Drugs use chemotherapy , melphalan , carboplatin , etoposide phosphate , work different way stop growth tumor cell , either kill cell stop dividing . Osmotic blood-brain barrier disruption ( BBBD ) use mannitol open blood vessel around brain allow cancer-killing substance carry directly brain . Sodium thiosulfate may help lessen prevent hearing loss toxicity patient undergo chemotherapy carboplatin BBBD . Giving carboplatin , melphalan , etoposide phosphate , mannitol , sodium thiosulfate together may effective treatment brain tumor .</brief_summary>
	<brief_title>Carboplatin , Melphalan , Etoposide Phosphate , Mannitol , Sodium Thiosulfate Treating Patients With Previously Treated Brain Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate toxicity estimate maximum tolerate dose ( MTD ) melphalan ( intra-arterially [ i.a . ] ) administer conjunction carboplatin ( i.a . ) etoposide phosphate ( intravenously [ i.v . ] ) undergo BBBD , subject anaplastic oligodendroglioma oligoastrocytoma . ( Phase I ) II . To examine efficacy ( one year progression free survival [ 1YPFS ] ) carboplatin ( i.a . ) , melphalan ( i.a . ) etoposide phosphate ( i.v . ) conjunction BBBD , subject anaplastic oligodendroglioma oligoastrocytoma . ( Phase II ) SECONDARY OBJECTIVES : I . To evaluate incidence severe neutropenia ( specifically febrile neutropenia sepsis ) carboplatin ( i.a . ) , melphalan ( i.a . ) etoposide phosphate ( i.v . ) conjunction BBBD , subject anaplastic oligodendroglioma oligoastrocytoma . II . To evaluate overall toxicity carboplatin ( i.a . ) , melphalan ( i.a . ) , etoposide phosphate ( i.v . ) conjunction BBBD . III . To estimate difference tumor response , 1YPFS survival , subject allelic loss chromosomes 1p 19q , tumor protein p53 ( p53 ) immunocytochemistry , versus subject without allelic loss . IV . To assess quality life , cognitive function , performance status subject undergoing treatment carboplatin , melphalan etoposide phosphate conjunction BBBD . V. To estimate difference 1YPFS subject anaplastic oligodendroglioma patient oligoastrocytoma . VI . To describe role biopsy versus extent surgery ( sub-maximal versus maximal safe resection ) 1YPFS survival . VII . To describe role prior radiation tumor response , 1YPFS survival . OUTLINE : This phase I , dose-escalation study melphalan follow phase II study . Patients receive etoposide phosphate IV 10 minute , mannitol IA 30 second , melphalan IA 10 minute , carboplatin IA 10 minute day 1 2 . Patients receive sodium thiosulfate IV 15 minute 4 8 hour carboplatin . Courses repeat every 4 6 week 12 month . After completion study treatment , patient follow every 3 month 1 year , every 6 month 2 year , annually thereafter .</detailed_description>
	<mesh_term>Oligodendroglioma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Mechlorethamine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Nitrogen Mustard Compounds</mesh_term>
	<mesh_term>Mannitol</mesh_term>
	<mesh_term>Sodium thiosulfate</mesh_term>
	<criteria>Subjects pathologic evidence anaplastic oligodendroglioma mixed glioma ( i.e . oligoastrocytoma ) eligible ; histopathologic diagnosis make use World Health Organization classification criterion ; qualify mixed tumor must minimum 25 % oligodendroglial element Surgical procedure may complete resection , partial resection , biopsy Subjects must prior treatment temozolomide ; least 28 day must elapse since completion temozolomide chemotherapy If subject undergone radiation therapy , subject must undergo prior consultation radiation oncologist ( investigator study ) ; subject undergone radiation therapy , least 14 day must elapse since completion radiation Subjects performance status must ( Karnofsky performance status [ KPS ] great equal 50 ; Eastern Cooperative Oncology Group [ ECOG ] less equal 2 ) White blood cell count &gt; = 2.5 x 10^3/mm^3 Absolute granulocyte count &gt; 1.5 x 10^3/mm3 Platelets &gt; = 100 x 10^3/mm^3 Serum creatinine &lt; 1.5 x upper limit normal Bilirubin &lt; 1.5 x upper limit normal Subjects baseline serum glutamic oxaloacetic transaminase ( SGOT ) /serum glutamate pyruvate transaminase ( SGPT ) must &lt; 2.5 x institutional upper limit normal Subjects must sign write informed consent accordance institutional guideline Sexually active woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study treatment duration study treatment ; woman become pregnant suspect pregnant participating study , inform treat physician immediately Subjects radiographic sign excessive intracranial mass effect associate rapid neurologic deterioration , and/or spinal cord block Subjects significant risk general anesthesia Subjects uncontrolled ( last 30 day ) clinically significant confound medical condition Subject pregnant , positive serum human chorionic gonadotropin ( hCG ) lactate Subjects contraindication carboplatin , melphalan , etoposide phosphate , sodium thiosulfate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>